MADRIGAL PHARMACEUTICALS, INC. MDGL

Madrigal Pharmaceuticals’ strongest current evidence is the commercial step visible in its SEC rail: the 10-Q for the period ending 2026-03-31 reports revenue from contract with customer, excluding assessed tax, of $311.3M, with product revenue, net shown as $311.3M versus $137.2M for the period ending 2025-03-31. The same filing says the company began generating revenue from sales of Rezdiffra in the United States in April 2024.

This is an equity story about an operating drug business, not just a ticker label. Madrigal Pharmaceuticals, Inc. is tied here to Rezdiffra sales, customer concentration disclosure, inventory and the cash demands of commercial execution. The supplied 10-Q says customers accounting for more than 10% of total gross product revenue mattered during the three months ended March 31, 2026 and 2025, which makes the customer rail part of the story rather than background furniture.

The latest supplied financials show a company with real revenue and real losses in the same frame. For the 10-Q period ending 2026-03-31, Madrigal reported net income loss attributable to parent of negative $94.4M, operating income loss of negative $92.7M, diluted EPS of negative $3.25 and weighted average diluted shares outstanding of 29.0M. Assets were $1.23B, liabilities were $683.9M and stockholders’ equity attributable to parent was $543.5M. Cash and cash equivalents were $227.0M, while net cash used in operating activities was negative $167.4M.

The source route supplied for this file is SEC EDGAR, including the 10-Q, the May 6 2026 8-K announcing first-quarter financial results, the June 17 2026 8-K, the company filing index, submissions JSON, companyfacts JSON and several June 18 2026 Form 4 ownership filings. No chart route, candle data, price level, volume figure or technical indicator is supplied, so the market mechanism that can be described here is filing-driven: revenue conversion, operating losses, cash use, inventory build, customer concentration and governance or ownership disclosures.

The named public developments are specific and narrow. SEC EDGAR shows multiple MDGL Form 4 filings dated 2026-06-18. The June 17 2026 8-K says stockholders approved Madrigal Pharmaceuticals, Inc. matters at the annual meeting, including approval language tied to Madrigal Pharmaceuticals, Inc. The May 6 2026 8-K says Madrigal issued a press release announcing financial results for the quarter ended March 31, 2026.

What the current file does not prove matters as much as what it does. It does not supply a share-price move, analyst action, guidance figure, dividend, buyback, clinical update, new approval or market-share statistic. The evidence supports a sharper, narrower conclusion: Madrigal’s current story is a Rezdiffra revenue ramp set against operating losses, cash use and fresh SEC filing activity.